Systemic anti-cancer therapy:
management options for people with squamous non-small-cell carcinoma – October 2020 update

**PD-L1 <50%**
- Gemcitabine + Carboplatin* or Cisplatin
- Vinorelbine + Carboplatin or Cisplatin

**PD-L1 ≥50%**
- Pembrolizumab (if PD-L1 >1%) (TA428)
- Pembrolizumab + carboplatin and paclitaxel (TA600)

**PD-L1 <50%**
- Pembrolizumab + carboplatin and paclitaxel (TA600)
- Atezolizumab (no PD-L1 expression needed) (TA520)
- Nivolumab (no PD-L1 expression needed) (TA655)
- Pembrolizumab (TA531)

**PD-L1 ≥50%**
- Pembrolizumab (TA531)
- Vinorelbine + Carboplatin or Cisplatin

---

This is a summary of the options for drug treatment for people with non-squamous and non-small-cell carcinoma in line with the NICE guideline on lung cancer. It also covers recommendations from technology appraisals published since 2009. Please refer to NICE technology appraisals and the NHS England website for information on eligibility, patient access schemes and more. See the NICE Pathway on lung cancer for an integrated view of all NICE recommendations on lung cancer. © NICE 2020. All rights reserved. Subject to Notice of rights.